LIFE SCIENCE  | 
PHYSICAL SCIENCE  | 
RESEARCH TOOLS  | 
SOFTWARE AND COPYRIGHT
TECHNOLOGY COMMERCIALIZATION HOME  | 
SEARCH
Search Results - cancer
15
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Discovery of Well Defined Sulfated Glycopolymers as Specific Heparanase Inhibitors for
Cancer
Therapeutics
The remodeling of the extracellular matrix has been shown to be highly upregulated in
cancer
and inflammation and is critically linked to the processes of invasion and metastasis. The finding that heparanase is elevated in a wide variety of tumor types and is subsequently linked to the development of pathological processes has led to an explosion of...
Published: 12/2/2020
|
Inventor(s):
Hein Nguyen
,
Ravi Loka
,
Eric Sletten
,
Israel Vlodavsky
Keywords(s):
Cancer
,
Cancer
Therapies
,
Pharmaceuticals
,
Therapeutics
Category(s):
Life Science
,
Oncology
,
Pharmaceuticals
,
Therapeutics
A method to induce ferroptosis and to downregulate androgen receptor/androgen receptor splice variant in prostate
cancer
cells
Prostate
cancer
(PCa) effects approximately three million men in the United States every year. About 10-20% of the cases of prostate cancer are castrate-resistant prostate cancer (CRPC). This form of PCa is highly resistant to what Is known as androgen depletion therapy and is often fatal. All types of PCa are sensitive to androgen receptor signaling...
Published: 10/26/2023
|
Inventor(s):
Zhihui Qin
,
Liping Xu
Keywords(s):
Anti-
cancer
,
Cancer
,
Cancer
Therapies
,
Drug Delivery
,
Drug Target
,
Prostate
Cancer
Category(s):
Medical
,
Diseases
,
Drug Discovery
,
Pharmaceuticals
,
Oncology
Fc-folate conjugate for the treatment of triple negative breast
cancer
Approximately 13% of women in the United States will develop breast
cancer
according to the American Cancer Society. That makes breast cancer the second leading cause of cancer death in women right behind lung cancer. Triple negative breast cancer (TNBC) represents about 10 – 20% of all breast cancers. Triple negative refers to cancer cells...
Published: 12/7/2022
|
Inventor(s):
Cecilia Speyer
Keywords(s):
Anti-
cancer
,
Breast
Cancer
,
Cancer
,
Cancer
Therapies
Category(s):
Antibodies
,
Assays
,
Biology
,
Biomedical
,
Chemical Processing/Synthesis
,
Diseases
,
Drug Delivery
,
Life Science
,
Oncology
,
Protein/peptides
,
Receptors/targets
,
Small molecule
,
Therapeutics
Inhibitors of the ubiquitin E3 ligase BCA2 as anti-
cancer
therapeutic agents
Background:Breast
cancer
associated protein 2 (BCA2) is a ubiquitin E3 ligase found in invasive breast cancer. Studies have shown that by decreasing its activity, breast cancer cell growth and invasiveness are diminished. Targeting this ligase and inhibiting its activity could play a role in treatment of breast cancer. A molecular approach to inhibiting...
Published: 3/12/2018
|
Inventor(s):
Angelika Burger
,
Andrew Westwell
Keywords(s):
Analog or Analogue
,
Breast
Cancer
,
Cancer
,
Disease
,
Drug Target
,
Enzyme
Category(s):
Diseases
,
Oncology
,
Therapeutics
,
Life Science
,
Research tools
ERK-Mediated Grb7 Phosphorylation: A Biomarker and Potential Therapeutic Target in Her2/Grb7 Amplified
Cancer
s
This invention is a new bio-marker for breast and other
cancer
s that have Her2 and Grb7 gene amplifications, thus providing a therapeutic intervention in Her2/Grb7 amplified cancers.Background40% of breast cancers, as well as several other cancer types, display increased activation of tyrosine kinases from the ErbB family, with Her2 found amplified...
Published: 3/12/2018
|
Inventor(s):
Guri Tzivion
,
Deborah Leicht
,
Alexander Kaplun
,
Stephen Ethier
Keywords(s):
Biomarker
,
Biotechnology
,
Cancer
,
Cancer
Therapies
,
Therapeutics
Category(s):
Diagnostic
,
Life Science
,
Oncology
Modified Ectodomain of Human EGFR as a Potential Anti
cancer
Agent
Development of a protein that attenuates EGFR and/or EGFR family members and is comprised of a modified EGFR ectodomain. The protein inhibits signaling via the EGFR and/or EGFR family members. The protein includes a portion of the EGFR (or EGFR family member) and the "U" region epitope of EGFR related protein (ERRP), wherein the portion of...
Published: 8/16/2021
|
Inventor(s):
Adhip Majumdar
,
Arun Rishi
,
Yingjie Yu
Keywords(s):
Breast
Cancer
,
Cancer
,
Cancer
Therapies
,
Disease
,
Drug Target
,
Protein
,
Therapeutics
Category(s):
Life Science
,
Biologicals
,
Diseases
,
Oncology
Translation Regulated (TR)-Mediated Gene Expression: Novel Expression and Reporter Vectors
Background: Often referred to as the crucial "drug discovery tool", cell based technology is one of the most significant sectors of pharmaceutical research and development. Of particular importance has been the development of information-rich cellular assays that determine drug candidate efficacy and safety (target identification, validation...
Published: 4/17/2022
|
Inventor(s):
Leon Carlock
,
Maria Cypher
Keywords(s):
Animal Model
,
Anti-
cancer
,
Cancer
,
Cancer
risk
,
Cancer
Therapies
,
Diagnostics
,
Imaging
,
Therapeutics
Category(s):
Life Science
,
Diagnostics
,
Research tools
,
Assays
,
Cell lines
,
Oncology
Ruthenium-based caging of nitrile-containing enzyme inhibitors
Technology Summary: Novel synthesis methods for caging nitrile-containing bioactive molecules to a non-toxic ruthenium metal complex have been developed which enable light activated release of a cathespin K inhibitor. Numerous potent and selective cathepsin inhibitors are being developed as drug candidates. Cysteine cathepsins are involved in the pathophysiology...
Published: 10/27/2023
|
Inventor(s):
Jeremy Kodanko
,
Claudia Turro
Keywords(s):
Cancer
,
Pharmaceuticals
Category(s):
Chemicals
,
Drug Delivery
,
Life Science
,
Physical Sciences
,
Other
Dual action nanocarrier combining CXCR4 antagonist and polyplex gene delivery for treatment of metastatic
cancer
and other diseases
Novel bio-reducible polymer compositions which combine the ability to act as a CXCR4 antagonist and simultaneously provide enhanced gene delivery through the formation of inert nanocarrier polyplexes have been developed. As would be expected for biodegradable polymers, the cytotoxicity of these nanocarrier compositions are very low with measured IC50...
Published: 11/11/2021
|
Inventor(s):
David Oupicky
,
Jing Li
Keywords(s):
Cancer
,
Cancer
Therapies
,
Compound
,
Drug Delivery
,
Drug Target
,
Formulation
,
Imaging
,
Nanomaterials
,
Pharmaceuticals
,
Therapeutics
Category(s):
Drug Delivery
,
Gene Therapy
,
Therapeutics
,
Life Science
,
Oncology
,
Nano-based
,
Metabolic disorders
,
Biologicals
Establishment of a Metastatic Prostate Carcinoma Tumor Model in Mice
This technology is a new tumorigenic cell line from the human prostate carcinoma cell line PC-3. These cell lines, known as PC-3/PI, are highly tumorigenic when implanted in the prostate of nude mice, providing a xenograft tumor model of prostate carcinoma. In this model, lymph node metastases form from the primary tumor, similar to what occurs in...
Published: 9/16/2019
|
Inventor(s):
Gilda Hillman
Keywords(s):
Animal Model
,
Cancer
,
Prostate
Cancer
,
Research Tool
Category(s):
Animal models
,
Life Science
,
Oncology
,
Research tools
,
Diseases
1
2